Results 181 to 190 of about 52,891 (241)

Pharmacotherapy Risks in Rare Genetic Diseases: Cross‐Referencing ACMG Secondary Findings v3.2 List With Clinical Databases

Clinical and Translational Science, Volume 19, Issue 1, January 2026.
ABSTRACT Clinical genomics and pharmacogenomics have largely remained separate fields, though some genetic variants have overlapping disease risk and drug implications. However, the extent of this overlap is not well studied. To explore this gap, we cross‐referenced genes from the American College of Medical Genetics Secondary Findings v3.2 list with ...
Josiah D. Allen, Benjamin Q. Duong, Jordan Brady, Pamela Arn   +3 more
wiley   +1 more source

Left Ventricular Apical Thrombus in Apical Hypertrophic Cardiomyopathy Without Aneurysm or Arrhythmia: A Case Report. [PDF]

Catheter Cardiovasc Interv
Antoun I, Khoo J, Bhandari SS.
europepmc   +1 more source

The fat‐heart entanglement and the role of ‘osteopontin mechanics’ in cardiometabolic senescence

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Abstract Background Residual cardiovascular (CV) risk persists despite therapeutic advances. Obesity is heterogeneous, and visceral adipose tissue (VAT) dysfunction (‘adiposopathy’) complicates risk stratification. Osteopontin (OPN) is a pleiotropic mediator implicated in VAT inflammation, senescence‐associated pathways, atherosclerosis and myocardial ...
Cristina Michelauz, Fabrizio Montecucco, Luca Liberale, Federico Carbone   +3 more
wiley   +1 more source

Correction: The rise of rat models for Duchenne muscular dystrophy and therapeutic evaluations. [PDF]

Skelet Muscle
Relaix F, Lafuste P, Taglietti V, Tiret L.   +3 more
europepmc   +1 more source

Cellular Senescence, Inflammaging and Cardiovascular Disease

Immunological Reviews, Volume 337, Issue 1, January 2026.
ABSTRACT Aging is the most important yet unmodifiable risk factor for cardiovascular disease (CVD). As a result, targeting cardiovascular aging has emerged as a promising strategy to promote long‐term cardiovascular health. This review summarizes current knowledge on the effects of aging within the cardiovascular system as well as systemic processes ...
Lukas Zanders, Denada Arifaj, Julian U. G. Wagner, Stefanie Dimmeler   +3 more
wiley   +1 more source

Before taurine is recommended for stroke-like epsiodes in m.3243A>G carriers, its efficacy must be demonstrated by appropriate studies. [PDF]

CEN Case Rep
Finsterer J.
europepmc   +1 more source

Cardiac fibrosis induced by high‐fat diet in ApoE‐deficient male mice is exacerbated by genetic deletion of PACAP–PAC1 signaling

Journal of Neuroendocrinology, Volume 38, Issue 1, January 2026.
Abstract Cardiac fibrosis is characterized by an excessive accumulation of extracellular matrix proteins and occurs in a variety of cardiac diseases, such as the highly prevalent syndrome heart failure with preserved ejection fraction (HFpEF) and other cardiac disorders.
J. M. Schubart, M. K. H. Schaefer, G. A. Bonaterra, L. Mey, H. Schwarzbach, S. Pankuweit, F. Ausbuettel, L. E. Eiden, S. Weyand, E. Weihe, R. Kinscherf, C. Waechter   +11 more
wiley   +1 more source

Danon disease: Two case reports and literature review. [PDF]

Medicine (Baltimore)
Yu K, Peng B, Zhao D, Wang Y.
europepmc   +1 more source

Low‐Dose Mavacamten Initiation in Obstructive Hypertrophic Cardiomyopathy: A Real‐World Study in China

Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.
Aims To evaluate the real‐world efficacy and safety of low‐dose (2.5 mg) mavacamten initiation in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Methods and Results This single‐center observational study (Zhongshan Hospital, China; Oct 2024–Apr 2025) enrolled 72 symptomatic oHCM patients (NYHA II/III, LVEF ≥ 55 ...
Wenlong Yang, Hui Shi, Rebecca Suchi Chang, Yin Zhang, A. Jixiang, Chunyu Wu, Juying Qian, Junbo Ge, Shuning Zhang, Baohui Xu   +9 more
wiley   +1 more source

MicroRNA mediated regulation in early-onset cardiac hypertrophy: Insights from the hypertrophic heart rat model. [PDF]

PLoS One
Sadiq S, Charchar FJ, Sanigorski A, Crowley T, Bookun HR, McClure DN.   +5 more
europepmc   +1 more source